When considering the risks and bene ts of extended anticoagulation in this update, the AT10 panel decided TABLE 12 ] Summary of Findings: 6, 12, or 24 mo vs 3 or 6 mo as Minimum Duration of Anticoagulation for VTEa,b Outcomes No. of Participants (Studies) Follow-up Quality of the Evidence (GRADE) Relative Effect Anticipated Absolute Effects Risk with No Extended Use Risk Difference with E xtended Use (95% CI) Moderatec,d,e because of imprecision (from 4 fewer to 46 more) Recurrent VTE 2,466 Moderatec,d,e because of imprecision (from 40 fewer to 8 more) Major bleeding 2,466 Moderatec,d,e because of imprecision (from 1 fewer to 27 more) The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). DACUS Warfarin Optimal Duration Italian Pulmonary Embolism; DOTAVK Dur e Optimale du Traitement AntiVitamines K; WODIT-DVT Warfarin Optimal Duration Italian Deep Vein Thrombosis; WODIT-PE Warfarin Optimal Duration Italian Pulmonary Embolism. See Table 1, 4, and 6 legends for expansion of other abbreviations and GRADE Working Group grades of evidence. a Studies vary in follow-up duration (10 mo-3 y) and in duration of time-limited VKA (3-6 mo). b VKA as NOACs are not included. c Timing of randomization relative to the start of treatment and length of treatment varied across studies: Pinede et al223 and Campbell et al222 randomized at diagnosis; and Agnelli et al,223 Eischer et al,227 and Couturaud et al60 randomized after the initial 3 mo (Agnelli et al224 ) or 6 mo (Eischer et al227 Couturaud et al60 ) of treatment to stop or continued treatment. 